Evidence map›Paper›PMID 24963723›Full record

ArticleCell cycle (Georgetown, Tex.)2014

ZMYND11: an H3.3-specific reader of H3K36me3.

Hong Wen, Yuanyuan Li, Haitao Li, Xiaobing Shi

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The role of HIRA-dependent H3.3 deposition and its modifications in the somatic hypermutation of immunoglobulin variable regions.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Histone H3.3 and cancer: A potential reader connection.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Hong WenDepartment of Molecular Carcinogenesis; The University of Texas MD Anderson Cancer Center; Houston, TX, USA; Center for Cancer Epigenetics; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
Yuanyuan LiDepartement of Basic Medical Sciences; School of Medicine; Tsinghua University; Beijing, China; MOE Key Laboratory of Protein Sciences; Center for Structural Biology; School of Life Sciences; Tsinghua University, Beijing, China.; Tsinghua-Peking Center for Life Sciences; Tsinghua University; Beijing, China.
Haitao LiDepartement of Basic Medical Sciences; School of Medicine; Tsinghua University; Beijing, China; MOE Key Laboratory of Protein Sciences; Center for Structural Biology; School of Life Sciences; Tsinghua University, Beijing, China.
Xiaobing ShiDepartment of Molecular Carcinogenesis; The University of Texas MD Anderson Cancer Center; Houston, TX, USA; Center for Cancer Epigenetics; The University of Texas MD Anderson Cancer Center; Houston, TX USA; The University of Texas Graduate School of Biomedical Sciences; Houston, TX USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Transcription Elongation, GeneticAnimalsBreast NeoplasmsCarrier ProteinsFemaleHistonesHumansLysineRNA Polymerase IICarrier ProteinsHistonesLysineRNA Polymerase IIH3.3H3K36 trimethylationhistone variantPWWP domainZMYND11

Identifiers

PMID24963723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.